| Literature DB >> 28521771 |
Riitta Sauni1, Panu Oksa2,3, Jukka Uitti2,3,4, Asko Linna5, Raimo Kerttula6, Eero Pukkala7,8.
Abstract
BACKGROUND: There is inadequate evidence for the carcinogenicity of cobalt and cobalt compounds in humans. Consequently, the International Agency for Research on Cancer (IARC) has evaluated cobalt metal without tungsten carbide as possibly carcinogenic to humans (Group 2B). The aim of the study was to assess the risk of cancer among workers employed in a Finnish cobalt plant since the beginning of production in 1968.Entities:
Keywords: Cancer; Cobalt; Incidence; Occupational exposure
Mesh:
Substances:
Year: 2017 PMID: 28521771 PMCID: PMC5437691 DOI: 10.1186/s12885-017-3333-2
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Number of male workers (N) in cobalt plant cohort, and person-years during 1969–2013, by age and exposure group (for definitions, see Table 2). The numbers in the N column in different age groups refer to the age at the beginning of follow-up
| N | Person-years | |
|---|---|---|
| Total | 995 | 26,083.2 |
| High exposure | 380 | 11,254.9 |
| Age (years) | ||
| 15–29 | 269 | 1480.0 |
| 30–44 | 103 | 4243.6 |
| 45–59 | 7 | 3663.5 |
| 60–74 | 1 | 1736.5 |
| 75+ | - | 131.6 |
| Moderate exposure | 159 | 2823.4 |
| Age (years) | ||
| 15–29 | 122 | 563.4 |
| 30–44 | 35 | 1378.4 |
| 45–59 | 2 | 674.8 |
| 60–74 | - | 205.8 |
| 75+ | - | 1.0 |
| Low exposure | 364 | 9966.7 |
| Age (years) | ||
| 15–29 | 275 | 1431.2 |
| 30–44 | 81 | 3903.3 |
| 45–59 | 8 | 2987.7 |
| 60–74 | - | 1522.6 |
| 75+ | - | 121.9 |
| Variable exposure with peak exposures | 110 | 2174.1 |
| Age (years) | ||
| 15–29 | 94 | 475.9 |
| 30–44 | 16 | 960.6 |
| 45–59 | - | 551.2 |
| 60–74 | - | 182.8 |
| 75+ | - | 3.7 |
Exposure groups according to departments
| Definition | Departments |
|---|---|
| Variable exposure with peak exposures | Factory maintenance |
| Low exposure | Leaching and solution purification |
| Moderate exposure | Chemical department, test plant |
| High exposure | Sulphatising roasting, reduction and powder production |
Fig. 1Cobalt production process in the Kokkola cobalt plant in 1966 – 1987 and 1987 – present
Fig. 2Mean cobalt exposure levels at Kokkola cobalt plant in 1968–2014
Observed (Obs) and expected (Exp) numbers of cancer cases and standardised incidence ratios (SIR) with 95% confidence intervals (CI) among male workers at the Kokkola cobalt plant during 1969–2013, by site and duration of employment. Only primary sites with ≥2 observed or expected cancer cases included
| Primary site | Employment >1 year | Employment >5 years | ||||||
|---|---|---|---|---|---|---|---|---|
| Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | |
| All sites | 92 | 91.9 | 1.00 | 0.81–1.22 | 77 | 71.6 | 1.08 | 0.85–1.34 |
| Tongue | 3 | 0.41 | 7.39 | 1.52–21.6 | 3 | 0.30 | 10.0 | 2.06–29.2 |
| Oesophagus | 2 | 1.15 | 1.74 | 0.21–6.28 | 2 | 0.89 | 2.24 | 0.27–8.08 |
| Stomach | 7 | 3.47 | 2.01 | 0.81–4.15 | 5 | 2.73 | 1.83 | 0.59–4.26 |
| Colon | 4 | 4.36 | 0.92 | 0.25–2.34 | 4 | 3.46 | 1.16 | 0.32–2.96 |
| Rectum, rectosigmoid | 4 | 3.80 | 1.05 | 0.29–2.69 | 3 | 2.93 | 1.03 | 0.21–2.99 |
| Pancreas | 2 | 3.44 | 0.58 | 0.07–2.09 | 1 | 2.69 | 0.37 | 0.01–2.07 |
| Larynx, epiglottis | 2 | 0.81 | 2.45 | 0.30–8.86 | 2 | 0.65 | 3.09 | 0.37–11.2 |
| Lung, trachea | 6 | 12.0 | 0.50 | 0.18–1.08 | 5 | 9.55 | 0.52 | 0.17–1.22 |
| Melanoma of the skin | 1 | 3.29 | 0.30 | 0.01–1.69 | 1 | 2.53 | 0.39 | 0.01–2.20 |
| Skin, non-melanoma | 3 | 2.78 | 1.08 | 0.22–3.15 | 3 | 2.22 | 1.35 | 0.28–3.94 |
| Basal cell carcinoma of the skin | 18 | 19.2 | 0.94 | 0.56–1.48 | 12 | 15.1 | 0.80 | 0.41–1.38 |
| Prostate | 33 | 24.4 | 1.35 | 0.93–1.89 | 26 | 19.4 | 1.34 | 0.87–1.96 |
| Kidney | 2 | 3.81 | 0.52 | 0.06–1.89 | 2 | 3.00 | 0.67 | 0.08–2.40 |
| Bladder and urinary tract | 9 | 4.79 | 1.88 | 0.86–3.56 | 6 | 3.76 | 1.60 | 0.59–3.47 |
| Brain, central nervous system | 2 | 2.82 | 0.71 | 0.09–2.56 | 2 | 2.07 | 0.97 | 0.12–3.49 |
| Thyroid gland | 2 | 0.99 | 2.01 | 0.24–7.26 | 2 | 0.72 | 2.78 | 0.34–10.0 |
| Non-Hodgkin lymphoma | 3 | 4.44 | 0.68 | 0.14–1.97 | 3 | 3.42 | 0.88 | 0.18–2.56 |
| Leukaemia | 3 | 2.11 | 1.42 | 0.29–4.15 | 3 | 1.58 | 1.90 | 0.39–5.54 |
Observed (Obs) and expected (Exp) numbers of cancer cases (all sites, lung and nasal cancer) and standardised incidence ratios (SIR) with 95% CI during 1967–2011 among workers in the Kokkola cobalt plant during 1969–2013with employment of >1 year, by exposure group
| Exposure group | All sites | Lung, trachea | Tongue | Bladder | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | |
| Variable | 7 | 5.02 | 1.39 | 0.56–2.87 | - | 0.55 | 0.00 | 0.00–6.68 | 1 | 0.04 | 26.4 | 0.67–14.0 | - | 0.25 | 0.00 | 0.00–15.0 |
| Low | 42 | 37.8 | 1.11 | 0.80–1.50 | 2 | 4.89 | 0.41 | 0.05–1.47 | 1 | 0.15 | 6.48 | 0.16–36.1 | 6 | 1.96 | 3.07 | 1.12–6.67 |
| Moderate | 4 | 6.02 | 0.66 | 0.18–1.70 | - | 0.66 | 0.00 | 0.00–5.56 | - | 0.06 | 0.00 | 0.00 | - | 0.30 | 0.00 | 0.00–12.2 |
| High | 39 | 43.6 | 0.90 | 0.64–1.22 | 4 | 5.95 | 0.67 | 0.18–1.72 | 1 | 0.16 | 6.12 | 0.15–34.1 | 3 | 2.32 | 1.30 | 0.27–3.78 |
| Total | 92 | 91.9 | 1.00 | 0.81–1.22 | 6 | 12.0 | 0.50 | 0.18–1.08 | 3 | 0.41 | 7.39 | 1.52–21.6 | 9 | 4.79 | 1.88 | 0.86–3.56 |